S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
S&P 500   3,373.23 (-0.38%)
DOW   29,219.98 (-0.44%)
QQQ   234.78 (-0.93%)
AAPL   320.30 (-1.03%)
FB   214.58 (-1.34%)
MSFT   184.42 (-1.53%)
GOOGL   1,516.99 (-0.52%)
AMZN   2,153.13 (-0.79%)
CGC   22.31 (+2.48%)
NVDA   308.70 (-1.91%)
BABA   218.04 (-1.85%)
MU   59.00 (-1.65%)
GE   12.53 (-0.63%)
TSLA   899.41 (-1.96%)
AMD   57.27 (-2.77%)
T   38.61 (+0.44%)
ACB   1.68 (-1.75%)
F   8.03 (+0.38%)
NFLX   386.00 (-0.05%)
BAC   34.85 (+0.37%)
DIS   140.37 (-0.66%)
Log in

NASDAQ:ZYNE - Zynerba Pharmaceuticals Stock Price, Forecast & News

$4.81
0.00 (0.00 %)
(As of 02/20/2020 04:00 PM ET)
Today's Range
$4.68
Now: $4.81
$4.93
50-Day Range
$4.49
MA: $5.32
$6.16
52-Week Range
$4.38
Now: $4.81
$16.47
Volume379,656 shs
Average Volume571,572 shs
Market Capitalization$111.58 million
P/E RatioN/A
Dividend YieldN/A
Beta4.59
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZYNE
CUSIPN/A
Phone484-581-7505

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90,000.00
Book Value$3.27 per share

Profitability

Net Income$-39,910,000.00

Miscellaneous

Employees25
Market Cap$111.58 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive ZYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter.


Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.52) by $0.08. View Zynerba Pharmaceuticals' Earnings History.

When is Zynerba Pharmaceuticals' next earnings date?

Zynerba Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Zynerba Pharmaceuticals.

What price target have analysts set for ZYNE?

7 brokers have issued twelve-month price objectives for Zynerba Pharmaceuticals' stock. Their forecasts range from $11.00 to $26.00. On average, they expect Zynerba Pharmaceuticals' share price to reach $17.83 in the next twelve months. This suggests a possible upside of 270.8% from the stock's current price. View Analyst Price Targets for Zynerba Pharmaceuticals.

What is the consensus analysts' recommendation for Zynerba Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynerba Pharmaceuticals.

What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (11/9/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We understand the market’s reaction when focusing on a few items: 1) There was a case of status epilepticus (SE); 2) 96% of patients reported an adverse event (AE); 3) 10/48 (21%) reported a serious adverse event (SAE); 4) Zygel doesn’t work fast enough; 5) 7 of 48 (15%) dropped out for efficacy; and 6) There were only 11 Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) patients. However, we find some perspective on these figures are important to consider: 1. SE has not been found in any previous Zygel trial, including the Phase 2s in adult refractory epilepsy (n=188), osteoarthritis of the knee (n=300) and Fragile X syndrome (FXS; n=16). As we have described in our notes on Buy), SE typically occurs in patients highly compromised by underlying health conditions and/or trauma." (9/18/2019)
  • 3. Cantor Fitzgerald analysts commented, "We rate ZYNE Overweight. We focus our valuation on FXS, where we are encouraged by the open-label, long-term data, with meaningful and durable improvements that we see having predictive value for the pbo-controlled pivotal CONNECT-FX trial. On epilepsy indications, we await further data after a disappointment in focal epilepsy. Section may be found on pages 4 – 5.We use a discounted NPV revenue calculation that yields ~$8 for ZYN002 in the U.S. FXS market and ~$3 in the EU." (3/7/2019)

Has Zynerba Pharmaceuticals been receiving favorable news coverage?

Headlines about ZYNE stock have been trending extremely negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zynerba Pharmaceuticals earned a news impact score of -4.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Zynerba Pharmaceuticals.

Are investors shorting Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 6,390,000 shares, an increase of 7.8% from the January 15th total of 5,930,000 shares. Based on an average daily trading volume, of 560,900 shares, the short-interest ratio is presently 11.4 days. Approximately 31.6% of the shares of the company are short sold. View Zynerba Pharmaceuticals' Current Options Chain.

Who are some of Zynerba Pharmaceuticals' key competitors?

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the folowing people:
  • Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 61)
  • Ms. Terri B. Sebree, Pres (Age 61)
  • Mr. James E. Fickenscher, CFO, VP of Corp. Devel. & Treasurer (Age 55)
  • Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 50)
  • Ms. Suzanne M. Hanlon, Sec., VP & Gen. Counsel (Age 62)

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (1.74%), Geode Capital Management LLC (1.20%), AdvisorShares Investments LLC (1.16%), Prentice Capital Management LP (0.90%), Campbell Capital Management Inc. (0.31%) and Bank of New York Mellon Corp (0.29%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, John P Butler, Michael Rapp and Terri B Sebree. View Institutional Ownership Trends for Zynerba Pharmaceuticals.

Which major investors are selling Zynerba Pharmaceuticals stock?

ZYNE stock was sold by a variety of institutional investors in the last quarter, including Campbell Capital Management Inc., New York State Common Retirement Fund and Claraphi Advisory Network LLC. View Insider Buying and Selling for Zynerba Pharmaceuticals.

Which major investors are buying Zynerba Pharmaceuticals stock?

ZYNE stock was acquired by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, Prentice Capital Management LP, Dynamic Technology Lab Private Ltd, State Street Corp, California Public Employees Retirement System, Cubist Systematic Strategies LLC, AQR Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher, John P Butler, Michael Rapp and Terri B Sebree. View Insider Buying and Selling for Zynerba Pharmaceuticals.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $4.81.

How big of a company is Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals has a market capitalization of $111.58 million and generates $90,000.00 in revenue each year. The company earns $-39,910,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Zynerba Pharmaceuticals employs 25 workers across the globe.View Additional Information About Zynerba Pharmaceuticals.

What is Zynerba Pharmaceuticals' official website?

The official website for Zynerba Pharmaceuticals is http://www.zynerba.com/.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]


MarketBeat Community Rating for Zynerba Pharmaceuticals (NASDAQ ZYNE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  587 (Vote Outperform)
Underperform Votes:  513 (Vote Underperform)
Total Votes:  1,100
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe ZYNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Featured Article: Roth IRA

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel